Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Cancer Radiother ; 16(4): 247-56, 2012.
Artigo em Francês | MEDLINE | ID: mdl-22652299

RESUMO

PURPOSE: Adenoid cystic carcinoma represents 1% of head and neck cancers. Adenoid cystic carcinomas are slow growing tumours with high potential for local recurrence. Treatment usually associates radiotherapy and surgery, but the role of radiotherapy remains unclear. We report a retrospective multicentric study of the management and prognostic factors of 169 adenoid cystic carcinomas of head and neck. PATIENTS AND METHODS: Between 1982 and 2010, 169 patients with adenoid cystic carcinoma of the head and neck were referred to the Cercle des oncologues radiothérapeutes du Sud departments of radiotherapy either for primary untreated tumour (n=135) or for a recurrence of previously treated tumour (n=34). The site of adenoid cystic carcinoma was: parotid gland (n=48, 28.4%), minor salivary gland (n=35, 20.7%), submandibular gland (n=22, 13%), sinus cavities (n=22, 13%), other (n=42, 24.9%). Tumour stages were: T1 (12.4%); T2 (14.2%); T3 (12.4%); T4 (41.4%) and Tx (19.5%). Lymph node involvement was 13% and distant metastasis 8.9%. For adenoid cystic carcinomas of the parotid gland, major nerve involvement was evaluated. Preferential site of metastasis was the lung (87.5%). Treatments were: surgery alone (n=27), surgery and adjuvant radiotherapy (n=89), surgery and adjuvant chemoradiotherapy (n=12), exclusive chemoradiotherapy (n=13), exclusive radiotherapy (n=14), other associations (n=5) and no treatment (n=7). Radiotherapy was delivered through photons (n=119), neutrons (n=6), both (n=4). Two patients had a brachytherapy boost. Median prescribed doses to T and N were respectively 65 Gy and 50 Gy for the 119 photons treated patients. RESULTS: Mean follow-up was 58 months (range 1-250 months). As of December 1, 2010, 83 patients were alive with no evolutive disease (49%), 35 alive and had recurred, 18 had uncontrolled evolutive disease, 28 had died of adenoid cystic carcinoma and 5 of intercurrent disease. Overall survival and disease free survival were respectively 72% and 72% at 5 years, 53% and 32% at 10 years; 5 and 10-year freedom from local recurrence were 81% and 52% respectively. Nerve involvement was found in 17/48 parotid gland adenoid cystic carcinomas. The Cox model including all patients, showed that surgery (P<0.001), surgical margins (P=0.015), nerve involvement (P=0.0079), length of radiotherapy (P=0.018), and tumour location (P=0.041) were associated with disease free survival. CONCLUSION: In this large series of adenoid cystic carcinoma of head and neck with a majority of T3-T4 tumours, 10-year survivals were achieved for 50% of patients. Radiotherapy did not impact survival.


Assuntos
Carcinoma Adenoide Cístico/terapia , Neoplasias de Cabeça e Pescoço/terapia , Adolescente , Adulto , Idoso , Idoso de 80 Anos ou mais , Criança , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Estudos Retrospectivos , Adulto Jovem
2.
Cancer Radiother ; 15(2): 89-96, 2011 Apr.
Artigo em Francês | MEDLINE | ID: mdl-20674447

RESUMO

PURPOSE: Surgery is the treatment of choice for localized uterine sarcomas. We conducted a retrospective study to define prognostic factors. PATIENTS AND METHODS: We studied 111 cases of patients treated by adjuvant radiotherapy for uterine sarcoma in seven French centers. The median decline was 31 months. We conducted a univariate analysis to identify factors correlated with local recurrence. The statistically significant factors were studied in multivariate analysis by Cox model. RESULTS: The median dose of external beam radiotherapy was 45 Gy. Forty-three percent of patients had vaginal vault brachytherapy and 21 % chemotherapy. Only 6.3 % of patients had complications of acute grade III and 8.1 % of long-term sequelae of radiotherapy. The survival rate at 5 years was 74.6 %. They noted 12.6 % of isolated locoregional recurrences, against 29.7 % for distant recurrences, 80 % were pulmonary. Factors correlated with the risk of locoregional relapse were menopausal status (P = 0.045) and surgical margins suspicious or not healthy (P = 0.0095). The chemotherapy did not improve overall survival or disease free survival but the numbers were low. CONCLUSION: The postoperative radiotherapy provides good local control in this disease. Brachytherapy is sometimes done, but it does not improve local control. Chemotherapy is not a standard localized stage but the rate of metastatic recurrence calls for the development of strategies involving systemic treatment with radiotherapy.


Assuntos
Carcinossarcoma/radioterapia , Tumores do Estroma Endometrial/radioterapia , Leiomiossarcoma/radioterapia , Neoplasias Uterinas/radioterapia , Análise de Variância , Braquiterapia/efeitos adversos , Braquiterapia/métodos , Braquiterapia/estatística & dados numéricos , Carcinossarcoma/mortalidade , Carcinossarcoma/patologia , Carcinossarcoma/secundário , Carcinossarcoma/terapia , Terapia Combinada/métodos , Tumores do Estroma Endometrial/mortalidade , Tumores do Estroma Endometrial/patologia , Tumores do Estroma Endometrial/secundário , Tumores do Estroma Endometrial/terapia , Feminino , França , Humanos , Histerectomia/métodos , Leiomiossarcoma/mortalidade , Leiomiossarcoma/patologia , Leiomiossarcoma/secundário , Leiomiossarcoma/terapia , Neoplasias Pulmonares/secundário , Pessoa de Meia-Idade , Recidiva Local de Neoplasia/mortalidade , Recidiva Local de Neoplasia/patologia , Prognóstico , Modelos de Riscos Proporcionais , Radioterapia/efeitos adversos , Dosagem Radioterapêutica , Estudos Retrospectivos , Análise de Sobrevida , Neoplasias Uterinas/mortalidade , Neoplasias Uterinas/patologia , Neoplasias Uterinas/terapia
3.
Cancer Radiother ; 14 Suppl 1: S182-8, 2010 Nov.
Artigo em Francês | MEDLINE | ID: mdl-21129662

RESUMO

Testicular cancer is rare, representing only 1 % of malignant tumors, but the most common cancer in young men, 15 to 35 years. Adjuvant radiotherapy after orchidectomy in testicular seminoma stage I, reduces risk of relapse. It aims to eradicate micro-metastatic disease in lymph drainage territories. In the case of adjuvant radiotherapy, the relapse-free survival of 96 % with an overall survival of 98 % at 5 years. The irradiation volume is made up of lymph nodes paraaortic which it is possible to add the ipsilateral renal hilum to the testicular lesion. The current recommended dose is 20 Gy in 10 fractions and 2 weeks, usually delivered by two antero-posterior beams. The acute toxicities, mainly represented by nausea and diarrhea are usually quickly resolved to the end of irradiation. Regarding toxicities long-term, preservation of semen should be considered after surgery because of fear of infertility post-treatment. The risk of second cancer associated with exposure to ionizing radiation, albeit small, is especially important to consider these patients to significant life expectancy. Nevertheless, developments in radiotherapy techniques and lower doses and irradiated volumes can probably reduce this risk further.


Assuntos
Seminoma/radioterapia , Neoplasias Testiculares/radioterapia , Adolescente , Adulto , Diarreia/diagnóstico por imagem , Intervalo Livre de Doença , Fracionamento da Dose de Radiação , Humanos , Incidência , Linfonodos/parasitologia , Linfonodos/efeitos da radiação , Masculino , Náusea/diagnóstico por imagem , Cintilografia , Radioterapia/efeitos adversos , Radioterapia/métodos , Dosagem Radioterapêutica , Seminoma/epidemiologia , Seminoma/patologia , Seminoma/cirurgia , Neoplasias Testiculares/epidemiologia , Neoplasias Testiculares/patologia , Neoplasias Testiculares/cirurgia , Adulto Jovem
4.
Cancer Radiother ; 14(4-5): 373-5, 2010 Jul.
Artigo em Francês | MEDLINE | ID: mdl-20430663

RESUMO

Clinical situations requiring protections of ovaries are mainly paediatric irradiations and pre-menopausal pelvic irradiations. The main complication of ovarian irradiation is the induced castration. Ovaries are extremely radiosensitive organs with strong interpersonal variations. The castrative effect of irradiation depends mainly on two factors: patient's age and the dose delivered to ovaries. The surgical technique of ovarian transposition allows to minimize the dose received by ovaries by taking them away, out of irradiation fields; the aim is to exclude them from the volume receiving 5 Gy or more, and if possible from those receiving 2 Gy. This technique becomes integrated into a multidisciplinary approach of conservation of fertility for patients exposed to other cytotoxic treatments.


Assuntos
Ovário/efeitos da radiação , Tolerância a Radiação , Radioterapia/efeitos adversos , Adulto , Fatores Etários , Criança , Feminino , Fertilidade/efeitos da radiação , Humanos , Menopausa Precoce/efeitos da radiação , Ovariectomia , Ovário/anatomia & histologia , Ovário/fisiologia , Pelve/anatomia & histologia , Pré-Menopausa/efeitos da radiação , Proteção Radiológica/métodos , Radioterapia/métodos , Dosagem Radioterapêutica , Adulto Jovem
5.
Cancer Radiother ; 14(4-5): 376-8, 2010 Jul.
Artigo em Francês | MEDLINE | ID: mdl-20418148

RESUMO

Although there is very little evidence for direct irradiation of the testes, they may receive significant doses, especially in the treatment of pelvic tumors in adults and in pediatrics. The exocrine function of the testis seems to be more sensitive to radiotherapy. There is a risk of sterility, even after low doses of radiation. In the adult or the child who has reached puberty, we should propose a self-preservation of semen prior to radiotherapy. In pre-pubescent children, the problem is more delicate. In all cases, it is necessary to limit the dose to the testicles without affecting the coverage of tumour volume. Patients and/or their caregivers should be systematically informed of the risk of infertility related to irradiation.


Assuntos
Tolerância a Radiação , Radioterapia/efeitos adversos , Testículo/efeitos da radiação , Adulto , Criança , Humanos , Hipogonadismo/diagnóstico por imagem , Infertilidade Masculina/diagnóstico por imagem , Infertilidade Masculina/prevenção & controle , Masculino , Preservação de Órgãos/métodos , Puberdade/efeitos da radiação , Cintilografia , Radioterapia/métodos , Dosagem Radioterapêutica/normas , Medição de Risco , Testículo/anatomia & histologia , Testículo/fisiologia , Revelação da Verdade
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...